BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

OBJECTIVES: BAY 81‐8973 (Kovaltry(®)), a full‐length, unmodified, recombinant human factor VIII, provided excellent bleeding control for patients with haemophilia A in the pivotal 1‐year LEOPOLD I trial. The LEOPOLD I extension evaluated long‐term efficacy and safety of BAY 81‐8973 prophylaxis. METH...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Haematol
Main Authors: Mahlangu, Johnny, Lopez Fernandez, Maria Fernanda, Santagostino, Elena, Lalezari, Shadan, Tseneklidou‐Stoeter, Despina, Beckmann, Horst, Church, Nikki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7383510/
https://ncbi.nlm.nih.gov/pubmed/32112434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13402
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados